Do IL6 rs1800795 and IL23R rs11209026 variants increase susceptibility to inflammatory bowel disease?

Inflammatory Bowel Disease (IBD) is increasingly understood through the lens of genetic susceptibility influencing the gut's mucosal immune response. The IL6 and IL23R genes are central to this interplay, particularly in the context of chronic inflammation and intestinal integrity.

Clinical and genetic evidence

The evidence for these specific genetic variants in IBD susceptibility is currently classified as plausible but shows varying levels of direct clinical support:

• IL6 rs1800795 (-174 G>C): This variant appears to influence the severity and phenotype of IBD rather than acting as a definitive diagnostic marker. Patients with the CC genotype often exhibit higher serum levels of IL-6 and C-reactive protein (CRP). Furthermore, the C allele has been linked to a younger age at diagnosis, suggesting it may accelerate or intensify the disease process.
• IL23R rs11209026: While direct clinical data for this specific SNP were less robust in recent findings, the broader IL23R gene is consistently implicated in IBD through genome-wide association studies (GWAS). It is established as a critical component of the Th17 signaling pathway, which is fundamentally linked to intestinal inflammation.

Mechanistic pathways

The connection between these polymorphisms and gut health is explained by the following biological mechanisms:

• Immune Activation: These variants modulate the Th17/STAT3 axis. IL-6 acts as a pro-inflammatory driver for Th17 cell differentiation, while IL-23 receptor signaling sustains this response. Overactivation of these pathways leads to persistent mucosal immune signaling.
• Barrier Dysfunction: High levels of pro-inflammatory cytokines, specifically IL-6 and the IL-23/Th17 axis, are known to downregulate essential tight junction proteins such as ZO-1, occludin, and claudins. This degradation of the physical barrier increases intestinal permeability.
• Microbial Dysbiosis: The resulting inflammatory environment and "leaky" barrier create a feedback loop that promotes dysbiosis. Genetic risk for IBD is correlated with reduced microbial diversity and a shift toward pro-inflammatory bacterial profiles, which often precedes the clinical onset of the disease.

Bottom line

The association between IL6 rs1800795 and IL23R rs11209026 and IBD susceptibility is plausible, primarily through their role in driving the Th17/STAT3 inflammatory axis. While they may function more as modulators of disease severity and barrier integrity than as primary causes, their impact on mucosal immune activation and subsequent intestinal dysfunction is well-supported by current pathophysiological models.